key: cord-0258232-bcjhsdt9
authors: Brockman, D. G.; Petronio, L.; Dron, J. S.; Kwon, B. C.; Vosburg, T.; Nip, L.; Tang, A.; O'Reilly, M.; Lennon, N.; Wong, B.; Ng, K.; Huang, K. H.; Fahed, A. C.; Khera, A. V.
title: Design and user experience testing of a polygenic score report: a qualitative study of prospective users
date: 2021-04-20
journal: nan
DOI: 10.1101/2021.04.14.21255397
sha: e30f045af2ba23721e66d122eb404f1b3cf5d438
doc_id: 258232
cord_uid: bcjhsdt9

Background: Polygenic scores - which quantify inherited risk by integrating information from many common sites of DNA variation - may enable a tailored approach to clinical medicine. However, alongside considerable enthusiasm, we and others have highlighted a lack of systematic approaches for score disclosure. Here, we review the landscape of polygenic score reporting and describe a generalizable approach for development of polygenic score disclosure tools for coronary artery disease. Methods: First, we assembled a working group of clinicians, geneticists, data visualization specialists, and software developers. The group reviewed existing polygenic score reports and then designed a two-page mock polygenic score report for coronary artery disease. We then conducted a qualitative user-experience study with this report and an interview guide focused on comprehension, experience, and attitudes. Interviews were transcribed and thematically analyzed for themes identification. Results: We conducted interviews with ten adult individuals (50% females, 70% without prior genetic testing experience, age range 20 to 70 years) recruited via an online platform. We identified three themes from interviews: (1) visual elements, such as color and simple graphics, enable participants to interpret, relate to, and contextualize their polygenic score, (2) word-based descriptions of risk and polygenic scores presented as percentiles were most often recognized and understood, (3) participants had varying levels of interest in understanding complex genomic information and therefore would benefit from additional resources that can adapt to their individual needs in real time. In response to user feedback, colors used for communicating risk were modified to minimize unintended color associations and odds ratios were removed. Of note, all 10 participants expressed interest in receiving this report based on their personal genomic information. Conclusions: Our findings describe a generalizable approach to develop and test a polygenic score disclosure tool that is desired by the general public. These results are likely to inform ongoing efforts related to polygenic score disclosure within clinical practice.

In a new era focused on preventive genomic medicine, polygenic scores have gained traction in clinical medicine as a method for stratifying individuals by disease risk -an approach that can enable targeted interventions [1] [2] [3] . This has led several commercial and academic groups to launch efforts to compute and report polygenic scores for patients and consumers. However, approaches for developing and reporting polygenic scores have been highly variable [4, 5] . While there have been efforts to standardize reporting of polygenic score development in scientific literature [6] , best practice guidelines for clinical reporting of polygenic scores do not yet exist.

Most of our understanding on optimal methods to report genetic risk is based on monogenic diseases, which are only partially transportable to polygenic score reporting [7] [8] [9] [10] [11] [12] . Polygenic score reporting is different from monogenic disease reporting in at least three ways: First, polygenic score results are calculated on the basis of hundreds to millions of single nucleotide polymorphisms and reported as continuous outcomes. Therefore, they cannot be summarized using Human Genome Variation Society (HGVS) nomenclature and classified by pathogenicity as is recommended for monogenic reports by the American College of Medical Genetics (ACMG), European Society of Human Genetics, and the Association for Clinical Genetic Science [13] [14] [15] [16] . Further, Farmer et al., recommends the use of a neutral statement of fact to summarize genetic results on a report, such as 'a change in gene XYZ was found' [17] . However, since a polygenic score can only be calculated on the basis of genome-wide variation and interpreted in the context of comparison to a population, a parallel statement does not exist.

Second, recommendations for clinical management based on polygenic scores have not been fully characterized and are therefore not discussed in expert guidelines such as the National Comprehensive Cancer Network and the United States Preventive Services Task Force [18, 19] . The absence of management guidelines based on polygenic scores is an obstacle for providing resources, references, and clinical guidance that both patients and clinicians value on a genomic test report [8] . Although the ACMG does not provide a specific recommendation to outline patient-specific recommendations and resources on a genomic result, they do state that it "is appropriate and helpful" [15] .

Third, the potential utility of polygenic scores has most often been described in the context of risk stratification across a population and disease prevention rather than absolute risk prediction and diagnosis [20] . Given this shift in reporting scope and intended use, we need to better understand how numerical, text, and visual elements included in a polygenic score report influence the overall message of the report and patient perceived actionability of the information.

Recommendations for designing genetic test reports for both patients and non-genetics providers published by Farmer and colleagues provide a foundation for the creation of genetic test reports that expand beyond diagnosis of a monogenic disease [17] . However, the authors concluded that additional research is needed to tailor these reporting recommendations for polygenic scores.

We recognized an unmet need for research on design of polygenic score reports, risk disclosure tools, and accompanying educational resources that could be understood by both patients and nonexpert clinicians. This gap in resources is particularly relevant given the increasing number of initiatives that aim to make polygenic scores accessible to many individuals at no to low costs through the United Kingdom Accelerating Detection of Disease Challenge, eMERGE network, direct-to-consumer genetic testing companies, and independent academic organizations [21, 22] . The vast scope of these projects will require new tools for polygenic score disclosure and education through new service delivery models that may rely on novel media for communicating with patients and consumers.

Here, we describe a generalizable approach for design of polygenic score reports using a usercentric approach, conduct a qualitative research study of user understanding and experience, and discuss new media that could enable a personalized and interactive experience with results from polygenic risk models.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 20, 2021. ;  https://doi.org/10.1101/2021.04.14.21255397 doi: medRxiv preprint

We selected coronary artery disease (CAD) as a representative example of an important complex disease where polygenic scores have been well-validated with respect to risk stratification [23] [24] [25] [26] . We assembled a working group that consisted of 2 cardiologists experienced with treating coronary artery disease and genetics research, 1 genetic counselor, 2 clinical genetic laboratory experts, 2 designers, and 1 software developer. Over a period of 6 months, members of the group worked on iterative design and content creation (Fig. 1) .

We first reviewed publicly available polygenic score reports, identified through PubMed, internet search, the Polygenic Score Catalog [27] , or provided through personal communication (Fig. 2) . Reports were reviewed for (1) platform for risk disclosure (report medium), (2) personalized numeric risk estimate, (3) color schemes used, and (4) recommendations and resources provided.

We developed a two-page polygenic score report that could be easily understood by both the general public and clinicians (Fig. 3) . The report consisted of five sections, each intended to explain a major concept to support polygenic score interpretation and application for coronary artery disease, aided by a visual representation: (1) Information about the participant, (2) Participant's score, (3) 'What is a polygenic score?' (4) 'What is coronary artery disease?' and (5) 'How can I reduce my risk of coronary artery disease?'. Additionally, the report included a "Frequently Asked Questions" section to address common questions, provide a technical explanation of the test, and link to external resources.

User experience of polygenic score risk disclosure tool Ten participants were recruited through UserInterviews.com, an online recruitment and scheduling platform using quota sampling to enroll a relatively equal number of individuals by gender, age, and education. Individuals were required to be 18 years of age or older, have English as their native language, and be residents of the United States since disease prevalence described in the report was specific to the United States population. Eligible participants were excluded if they reported a personal history of coronary artery disease or worked in a genetics-related field.

We developed an interview guide consisting of 36 questions and prompts (Additional file 1) on the basis of preliminary feedback received from the working group's colleagues, acquaintances, and family members. All participants provided consent to participate in the study, which involved both audio and video recording. Interviews were conducted by a visual designer trained in user experience research and a genetic counselor. Only the two facilitators and one participant were present for each session.

Interviews were conducted virtually over Zoom video conferencing and lasted one hour in total. At the start of each session, participants were allowed up to fifteen minutes to independently review a mock polygenic score report for coronary artery disease indicating risk in either the 95th percentile (n= 4), 56th percentile (n=3) or 5th percentile (n=3). The facilitators then asked the participant to describe their experience viewing the report while being prompted to answer questions using the interview guide.

Each interview was recorded, manually transcribed by a member of the research team, coded and analyzed by the facilitators using thematic analysis [28] . Recurrent themes were identified from the data, coded, and summarized. This study was approved by the Mass General Brigham Institutional Review Board (2020P003088).

We reviewed polygenic score reports from seven commercial and academic companies. Among these seven companies, coronary artery disease was the most commonly available polygenic score; others included type 2 diabetes and breast cancer. Reports were highly variable in terms of color, numeric risk estimate provided, categories used to describe amount of risk, and focus on resources and . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 20, 2021. ; https://doi.org/10.1101/2021.04.14.21255397 doi: medRxiv preprint recommendations for the disease of interest (Fig. 2 , Table 2 ) [2, [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] . Three companies (Myriad, Ambry, 23andMe) provided at least one report that integrated a polygenic risk score with other clinical risk factors to generate an absolute percentage of risk.

Two companies (Ambry and Myriad) required a clinician to order the polygenic score. Of note, polygenic scores requiring clinician involvement were limited to individuals of 'European ancestry' ( Table 2) ; an approach that is inconsistent with other clinical genetic tests. Both companies stated that the information provided on the report may be used to 'better guide your patient's medical management' or 'to assist in the development of a treatment plan' [29, 34] . All other reports were intended to be used only for research purposes and not to be used to guide medical management.

The remaining five companies allowed for a consumer-initiated assessment without the involvement of an individual's healthcare provider. These consumer-initiated polygenic score assessments were calculated based on either genotype or sequencing data generated from a new saliva sample sent in by the consumer or raw genotype data shared directly with the company by the consumer. Results from consumer-initiated assessments were communicated via consumer-facing online portals or a phone application.

Color was chosen as the main visual element to describe risk direction, using a scale from green, to grey, to red. This color scale was intended to leverage cultural associations of go-stop and cool-warm, with the grey serving as a neutral tone to represent average risk as the baseline for comparison. This color gradient was used across all risk-related visuals to bridge the relationship between an individual's polygenic score with the genetic component from which it comes [42] .

A risk score 'flag' containing the individual's risk category, percentile, and odds ratio was positioned on the scale from significantly reduced risk (left) to significantly increased risk (right). The flag highlighted the risk category and was displayed prominently with a solid color-coded background of . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 20, 2021. ; https://doi.org/10.1101/2021.04.14.21255397 doi: medRxiv preprint green, grey, or red. The body of the flag incorporated the same color-coding in the percentile and odds ratio text, calling attention to these values and reinforcing their association to risk direction. For this coronary artery disease polygenic score report, the working group chose to incorporate the following word-based descriptions to categorize risk: 'significantly reduced risk' (0-5th percentile), 'reduced risk' (6th-19th percentile), 'average risk' (20th-79th percentile), 'increased risk' (80th -94th percentile), and 'significantly increased risk' (95th -99th percentile). These categories were defined based on review of literature and expert consensus [43] .

The population distribution graph behind the risk score 'flag' was included to support percentile understanding, emphasizing where most people fall on the polygenic score. Labels were also placed below the distribution to further describe how many people were in each risk category. The risk gradient shared the same x-axis as the population distribution and percentile markers for consistency and repetition.

We included a textual description of the individual's polygenic score and an explanation of their percentile below the graph. The same color-coding was applied to words pertaining to percentile, odds ratio, and risk category for further repetition and consistency. We also included statistics on coronary disease prevalence to provide the reader with additional context about their risk.

One unique aspect of coronary artery disease is that regardless of an individual's genetic background, a healthy lifestyle is associated with reduced risk of the disease [44] . To communicate positive lifestyle changes that individuals can undergo to mitigate an increased genetic risk, we used simple graphics to describe seven ideal cardiovascular health measures described by the American Heart Association as Life's Simple 7: Managing blood pressure, controlling cholesterol, reducing blood sugar, exercising regularly, following a heart-healthy diet, maintaining normal weight, and stopping smoking [45] . The number of those metrics is a strong predictor of all-cause mortality and mortality from diseases of the circulatory system [43, 44] .

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 20, 2021. ; https://doi.org/10.1101/2021.04.14.21255397 doi: medRxiv preprint User experience testing to optimizing a polygenic score risk disclosure tool for coronary artery disease Interviews were conducted with ten participants (5 females, mean age 50.3 years, SD = 14.8, 7

without any prior genetic testing experience) ( Table 1 ). All (10/10) participants expressed interest in receiving this report based on their own genomic data.

We identified three themes from coded transcripts: (1) Visual elements, such as color and simple graphics, enable participants to interpret, relate to, and contextualize their polygenic score, (2) Wordbased descriptions of risk and polygenic scores presented as percentiles were most often recognized and understood by participants, (3) Participants had varying levels of interest in understanding complex medical and genomic information and therefore would benefit from resources that can adapt to their individual needs in real time.

Theme One: Visual elements, such as color and simple graphics, enable participants to interpret, relate to, and contextualize their polygenic score.

Color was the predominant design element that influenced participants' level of concern about their hypothetical genetic risk. As intended, participants successfully used color to interpret their report, and frequently referenced these color 'zones' in terms of bad/good, safe/danger, unanimously considering them to be intuitive and discussing their score in terms of where on the color gradient they are (Fig. 4a) .

"I started with the chart, um, the color chart there, that was the first thing I looked at… So, looking at a score I would feel obviously great if I was in any of the green colored areas." 

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 20, 2021. ; https://doi.org/10.1101/2021.04.14.21255397 doi: medRxiv preprint Participants expressed differences in their understanding of the population distribution curve, interpretation of the underlying data, and association to its meaning (Fig. 4b) . One participant (9) , who reported an undergraduate education level, was an outlier in their misinterpretation of the curve. This participant misinterpreted the height of the curve to represent the amount of risk, associating up with more risk/bad and down with less risk/good. However, other participants reported the curve on the risk disclosure tool to be helpful in their ability to interpret their score.

"It looks like most people are in the average section, like in the middle, like that's why the curve is bigger there, cuz there are more people between the 20th and 80th percentile and then there's less people with reduced risk and less people with increased risk based on their genetics." (Participant 1)

"the easiest to understand part of it is just the graphic itself… seeing I'm in that meaty part of the curve which generally, you know, says average and so I think that was helpful. … otherwise saying just someone's in, you know, 56th percentile doesn't really mean a lot to me." (Participant 3) Some participants even found comfort in knowing how many other people were in the same group as them. 

Participants' recognition of the DNA figure often did not provide additional context for understanding polygenic risk variants (Fig 4c) . For example, Participant 2 stated, "I know [the DNA figure] has something to do with like genetics, genes or something." Another participant stated, "I'm not . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 20, 2021. Other participants who were already familiar with genetic concepts found the graphic and supporting text to be useful, but still could not fully understand the concept of polygenic inheritance. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 20, 2021. 

In general, participants found the cardiology and lifestyle graphics to be recognizable, relatable, and helpful for understanding the topic of the risk disclosure tool (Fig. 4d) . When prompted to comment on their perception of the simple and familiar graphics of healthy lifestyle factors outlined by the American Heart Association, many participants took the opportunity to discuss their family medical history and their personal experience with these healthy lifestyle choices. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Word-based descriptions of risk that provide high level explanations were frequently used by participants to summarize their takeaways from the risk disclosure tool (Fig. 5) .

" So the key message I get out of that graph is that I have an average risk, I'm not low risk, but I don't have an increased risk either?" (Participant 3) Importantly, this risk description was often a cause for concern or comfort for some participants. When asked about information they found challenging in the 'My Score' section, many participants did not understand the odds ratio. In contrast to an odds ratio with an ambiguous range of possible results, participants often discussed their familiarity with percentiles and commonly used percentile as the key reference point to interpret their score.

"I don't think anyone that takes this test wants to see themselves anywhere beyond that 50that halfway mark..." (Participant 7)

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 20, 2021. Nevertheless, participants had different preferences for the depth of information that they desired in this tool (Fig. 6 ); Participant 6 articulated that "it would be great if you got a choice between" the amount of information you receive. For example, some participants appreciated seeing a simple statistic for coronary artery disease prevalence.

While information about disease prevalence was included twice in the risk disclosure tool in sentence format, some participants shared that they were interested in receiving more detailed information about prevalence to further personalize the information.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 20, 2021. Another topic for which participants had variable interest in receiving more information was the 'how to reduce your risk' section. While some participants were satisfied with the amount of information in this section, many participants, particularly those that received 'significantly increased risk' mock score report, communicated that they would like additional guidance on how to adopt healthy lifestyle factors. Some participants also indicated that other media, such as a website or a video, would be helpful for learning more about their score.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 20, 2021. ; https://doi.org/10.1101/2021.04.14.21255397 doi: medRxiv preprint Although not all participants felt that incorporating concrete numbers was critical for an interactive tool that layers lifestyle choices on genetic background. Rather, a direction and a broad estimate of magnitude would be sufficient.

"If you were to say okay, 'do these 5 things in your risk goes from 56th to 35th percentile'... I don't know what that means really. But if you were to say, 'you're going to go from this average risk to this, like, reduced risk, but your reduced risk is still at the higher end of the reduced' -then, yeah, I can get that a lot more." (Participant 3)

It was rare for participants to be completely satisfied with the information included in the risk report. Even though one participant stated that he received all of the information he "need[ed] to know . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 20, 2021 At the end of the user experience session, participants were asked a series of questions about how interested they would be in receiving a report such as this one and how comfortable they would feel viewing this information on their own. All participants were interested in receiving a polygenic score for coronary artery disease, particularly those with a family history. Additionally, all participants indicated that they would be okay reviewing their polygenic score for coronary artery disease on their own; although, five stated that they would want to discuss it with their doctor at a later time for clarification and personalization of the information.

Maybe even once a year." (Participant 6) For these individuals, it will be crucial for companies and researchers to consider this as they develop polygenic score risk disclosure tools that are made available directly to patients and consumers.

Although color was well-understood by participants, we modified colors used to convey risk throughout the report to reduce the strength of association. The red-orange color, which was used to convey high risk, was altered to add cooler undertones; the green color, which was used to convey reduced risk, was changed to a blue/teal. In addition, we removed the polygenic score odds ratio from the risk flag to emphasize the numeric estimate that resonated most with users --polygenic score percentile. Last, we created a video explainer to provide additional education and resources for users to learn more about polygenic scores [46] .

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 20, 2021. ; https://doi.org/10.1101/2021.04.14.21255397 doi: medRxiv preprint

In this qualitative study involving user experience testing of a polygenic score report for coronary artery disease, we describe a generalizable and reproducible process for designing a polygenic score report for a complex disease. Our findings highlight two key insights in genomic implementation of risk disclosure using polygenic scores, which provide important guidance for next steps (Fig. 7) .

First, heterogeneity in the design of existing polygenic score reports and disclosure tools will present challenges for studying risk perception and clinical utility. A successful model for designing risk disclosure tools should take into consideration components of user-centric design and the intended utility of the risk model. Even seemingly routine design and reporting aspects of a report such as choice of color, visual and numerical estimates can have dramatic impact on understanding and perception of risk. For example, our study demonstrated that color, which varied across mock reports, was an important element of design that strongly influenced risk perception. The strength of participants' redgreen color association merits consideration of the intended goal for the use of color in the score report:

enhancing readability, emphasizing key information, promoting perceived actionability, or sparking concern or comfort. For each of those goals, the choice of color would differ. In the case of the report in this study, the red-green color served strongly to spark concern or comfort.

Farmer et al. advises against the use of color to communicate results since the interpretation of color may vary from individual to individual. This recommendation is particularly relevant in our study given the lack of clarity surrounding clinical and personal utility of polygenic scores [47] . If color is used to convey the magnitude of disease risk and there are limited guidelines on how to mitigate this risk, we recommend that a clinician expert be made available to that patient or consumer to discuss this risk.

Further, when selecting colors to convey information about health risks, we should be mindful of the inherent limitations of using color, such as the varying cultural associations of different colors, and its weakened impact for individuals with color blindness [48, 49] . In future studies, it would be important to . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 20, 2021. ; https://doi.org/10.1101/2021.04.14.21255397 doi: medRxiv preprint consider alternative options, such as a monochromatic color scale [50] . This could simplify the amount of visual-decoding required by patients, and would lend itself better to describing less/more risk, rather than low/high risk, a subtlety that nevertheless has implications for risk perception.

In addition to color, participants often recalled percentile and 'risk category' as the key messages of the report. Although percentiles do not correspond to medical guidelines at this time, we chose to emphasize a percentile as the main result since it provided an unambiguous range of reference --0 to 100 --that was most understood by participants. Additionally, percentiles can be adjusted by genetic ancestry, self-reported race, and ethnicity. We removed the odds ratio from the report because it was poorly understood by participants and varies according to genetic ancestry, self-reported race, and ethnicity [51] . Before reporting a polygenic score as an odds ratio on a patient and clinician-facing report, the score should first be re-calibrated in a diverse cohort that is representative of the consumer or patient population receiving the score. Additionally, visuals that provide a simple explanation of an odds ratio should be included in this risk disclosure tool. An absolute risk estimate was not included in our report. At this time, we recognize that polygenic scores are less precise across populations and by integrating them with existing, problematic, race-corrected clinical risk models, we risk perpetuating and exacerbating health disparities [52, 53] .

To be transparent about the current limitations of polygenic scores for individuals of non-European ancestry, we included the following statement on page 1 of the report --'The predictive ability of the polygenic score is less accurate in individuals of non-European ancestries. We are working to improve this for future versions of the score.' One participant who self-identified as Black expressed concern about this limitation, but still recommended that we "go ahead, roll [the polygenic score] out [to everyone] and just let the non-European ancestry [individuals] know it's going to be a little long, plus or minus whatever variance...It's probably still worth rolling it out to everyone." (Participant 7) A second participant who self-identified as Black also appreciated knowing this information and suggested that . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 20, 2021 In the context of this study, we felt that it was appropriate to bin and assign risk categories by percentile to evaluate perceived value and meaning by participants. However, we appreciate the significance that these labels carry when clinical utility has yet to be established and when clinician experts are not involved in the return of these results. We encourage others in the field who are developing polygenic score reports and risk disclosure tools to recognize the significance of these labels for patients, consumers, non-expert clinicians, insurance companies, and proceed with caution.

Second, static genomic test reports that limit one's ability to explore results are not ideal for polygenic risk disclosure. Risk disclosure tools that enable patients and consumers to have a personalized, interactive experience with their genomic report should be developed for polygenic score disclosure. One such medium to consider for this purpose is reader-driven narrative visualization, sometimes referred to as 'Scrollytelling'. Reader-driven narrative visualizations are online, user-centric, interactive tools that enable dynamic storytelling through data visualization to educate the reader about complex concepts [54] . To date, this medium has been used to educate about public health issues such as the United States Measles outbreak in 2015 and the Covid-19 pandemic [55] [56] [57] . We see an unexplored opportunity to develop and evaluate the utility of reader-driven narrative visualization tools in the context of preventive genomic medicine to support personalized healthcare.

In the context of coronary artery disease, a reader-driven narrative visualization risk disclosure tool could provide patients with resources and guidance outside of physician-prescribed medications and tests. For example, some patients or consumers may benefit from additional resources or information about how to manage one's cholesterol through diet. While a report may not be able to provide specific . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 20, 2021. ; https://doi.org/10.1101/2021.04.14.21255397 doi: medRxiv preprint dietary recommendations, a report could consider referencing within the tool resources from the American Heart Association so that the patient can review them independently before discussing their result with a clinician. We anticipate that providing patients with the opportunity to be educated independently may also promote a more in-depth counseling experience between patients and their clinicians to discuss the individual's motivation for pursuing particular healthy lifestyle changes and any barriers they are facing to adopt this change. Lastly, reader-driven narrative visualization tools for polygenic score results could also facilitate expansion of accessibility options for patients and consumers, such as providing quick language translation of content and enabling audio playback of content for individuals with visual impairments.

This study has several limitations. First, given the speed at which polygenic score reports are being developed and modified, reports may have been updated since our review of existing reports. Second, we aimed to recruit a cohort of participants with diverse backgrounds (education/work experience, age, geographic location, race/ethnicity) using a national online recruitment platform. However, our sample size was small and likely does not reflect the experiences of all individuals who may receive a polygenic score for coronary artery disease. Future studies should be conducted with more individuals in the general public with diverse backgrounds and individuals with a personal history of coronary artery disease.

Third, this study did not evaluate the clinicians' experience viewing a polygenic score risk disclosure tool. It is important to acknowledge that clinicians may have different preferences for the design of a polygenic score risk disclosure tool than the general public, which could impede clear communication of information. As efforts for returning polygenic scores continue to advance, it will be important to assess perceived utility of report elements by clinicians with and without clinical genetics expertise, and to standardize terminology and thresholds for risk labeling by disease area.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 20, 2021. ; https://doi.org/10.1101/2021.04.14.21255397 doi: medRxiv preprint Fourth, all participants stated that they would feel motivated to change their behavior if they received the mock report shown to them in this study. While intent is critical to the process of adopting healthy lifestyle behaviors, prospective studies are needed to assess behavior change based on receipt of actual polygenic score reports for coronary artery disease.

Our qualitative study revealed that polygenic risk score disclosure presents a set of challenges that are not unique in genetics, but should be approached with additional prudence. This study demonstrated that polygenic score reporting tools, which promote informed and inclusive understanding of personal and family history was desired by participants.

Through personalized polygenic score reports that leverage dynamic, reader-driven narrative visualization approaches, there is a unique opportunity to pair genomic risk reporting with education, expand accessibility options, provide personalized health information and support, and ultimately empower individuals to stay healthy. Finally, there is a need for professional organizations to put forth guidelines and best practices for polygenic score disclosure and reporting. In particular, guidance is needed to standardize risk category nomenclature and corresponding percentile/odds ratio thresholds by disease area, numeric reporting requirements, information on score limitations, and disclaimers. 

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 20, 2021. ; https://doi.org/10.1101/2021.04.14.21255397 doi: medRxiv preprint Fig. 1 Developing a user-centered polygenic score report. An interdisciplinary team adopted a multi-step approach to create and iterate on a polygenic score report for coronary artery disease through a review of existing polygenic score reports and qualitative research methods.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 20, 2021. ; Fig. 2 Polygenic risk score report visuals. Polygenic risk scores were compared on the basis of numeric estimates reported, risk description and colors used. 'CAD' represents coronary artery disease. Fig. 3 Mock polygenic score reports for coronary artery disease. a. Page one of 5th percentile (significantly reduced risk) mock report. b. Page two of all reports. c. Page one of 95th percentile (significantly increased risk) and 56th percentile (average risk) mock reports a b c . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 20, 2021. ; https://doi.org/10.1101/2021.04.14.21255397 doi: medRxiv preprint Fig. 4 User experience testing results: Theme one. Visual elements, such as color and simple graphics, enable participants to interpret, relate to, and contextualize their polygenic score. a. Color was the predominant design element that influenced participants' level of concern about their hypothetical genetic risk. b. Participants expressed differences in their understanding of the population distribution curve, interpretation of the underlying data, and association to its meaning. c. Participants were often unclear on genetic concepts and felt that test limitations were underemphasized. d. Participants found the cardiology and lifestyle graphics to be recognizable, relatable, and helpful for understanding the topic of the risk disclosure tool.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 20, 2021. ; https://doi.org/10.1101/2021.04.14.21255397 doi: medRxiv preprint Fig. 5 User experience testing results: Theme two. Word-based descriptions of risk and polygenic scores presented as a percentile were most often recognized and understood by participants. a. 'Risk category' is an interpretation of the numeric polygenic risk estimate. b. 'Percentile' is a polygenic risk estimate -on a scale from 0 to 100 -describing a participant's location in a normal distribution. c. 'Odds ratio' is an estimate of risk that conveys magnitude of risk compared to 'average risk' of 1.0.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 20, 2021. ; https://doi.org/10.1101/2021.04.14.21255397 doi: medRxiv preprint Fig. 6 User experience testing results: Theme three. Participants had varying levels of interest in understanding complex medical and genomic information and therefore would benefit from resources that can adapt to their individual needs in real time.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 20, 2021. ; https://doi.org/10.1101/2021.04.14.21255397 doi: medRxiv preprint Fig. 7 Next steps in genomic risk disclosure.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 20, 2021. ; https://doi.org/10.1101/2021.04.14.21255397 doi: medRxiv preprint

Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting

Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High-and Moderate-Risk Breast Cancer Genes

Polygenic Prediction of Weight and Obesity Trajectories from Birth to Adulthood

Polygenic risk scores: from research tools to clinical instruments

Polygenic risk scores in the clinic: new perspectives needed on familiar ethical issues

Improving reporting standards for polygenic scores in risk prediction studies

Developing patient-friendly genetic and genomic test reports: formats to promote patient engagement and understanding

Enhancing genomic laboratory reports: A qualitative analysis of provider review

Enhancing genomic laboratory reports from the patients' view: A qualitative analysis

A comparison of genomic laboratory reports and observations that may enhance their clinical utility for providers and patients

Testing a best practices risk result format to communicate genetic risks. Patient Education and Counseling

Impact of a Patient-Facing Enhanced Genomic Results Report to Improve Understanding, Engagement, and Communication

Guidelines for diagnostic nextgeneration sequencing

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology

HGVS Recommendations for the Description of Sequence Variants

Recommendations for designing genetic test reports to be understood by patients and non-specialists

NCCN Guidelines Index Table of Contents Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Discussion

Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement

The personal and clinical utility of polygenic risk scores

The eMERGE Network: A consortium of biorepositories linked to electronic medical records data for conducting genomic studies

The UK strategy for rare diseases: 2020 update to the implementation plan for England

Polygenic Scores to Assess Atherosclerotic Cardiovascular Disease Risk

Clinical characteristics and treatment patterns of patients at high polygenic risk for coronary artery disease

What Is Familial Hypercholesterolemia, and Why Does It Matter? Circulation

Genomic Risk Prediction of Coronary Artery Disease in 480,000 Adults

The Polygenic Score Catalog: an open database for reproducibility and systematic evaluation. medRxiv

Thematic Analysis. Encyclopedia of Critical Psychology

AmbryScore for Breast Cancer

AmbryScore Sample Report 2-Unaffected Male at Increased Risk.pdf

AmbryScore Sample Report 4 -Affected Male at Increased Risk.pdf

Validation of a Polygenic Risk Score for Breast Cancer in Unaffected Caucasian Women Referred for Genetic Testing

Validation of a Prostate Cancer Polygenic Risk Score for Clinical Use

Myriad myRisk

Development and Validation of a Clinical Polygenic Risk Score to Predict Breast Cancer Risk. JCO Precision Oncology

Moving Beyond Clinical Risk Scores with a Mobile App for the Genomic Risk of Coronary Artery Disease | bioRxiv

Store -Health Traits

me: An Open-Source, Non-profit Tool for Using Data From Direct-to-Consumer Genetic Testing to Calculate and Interpret Polygenic Risk Scores

A Generalized Method for the Creation and Evaluation of Polygenic Scores

Beyond Memorability: Visualization Recognition and Recall

Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations

Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease

ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

New genetic test for heart attack risk launched for patients at Mass General | Broad Institute

Polygenic scores and Clinical Utility

Are You Selling the Right Colour? A Cross-cultural Review of Colour as a Marketing Cue

Points of view: Color blindness

Using Monochromatic Design Views to Avoid a Premature Fixation on Design Solutions. Hum Factors

Transethnic Transferability of a Genome-wide Polygenic Score for Coronary Artery Disease. Circ: Genomic and Precision Medicine

Current clinical use of polygenic scores will risk exacerbating health disparities

Hidden in Plain Sight -Reconsidering the Use of Race Correction in Clinical Algorithms

More Than Telling a Story: Transforming Data into Visually Shared Stories

Why Measles May Just Be Getting Started. Bloomberg

More than 2,508,000 people have died from the coronavirus worldwide. The Washington Post

How epidemics like covid-19 end (and how to end them faster